13F GuideFiling Basics
What is SEC Form 13F? Ultimate Guide to Institutional Equity Filings
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
AlphaSMO Research GuideRead Guide
CIK: 0001232621
Total reported value
$2.2B
$2.2B
128 檔
10.9%
In Q2 2024, Tang Capital Management LLC's U.S. equity holdings reached a combined market value of $2.2B, distributed across 128 disclosed stock positions.
During Q2 2024, Tang Capital Management LLC's portfolio maintained high stability with no major positional turnover, reflecting a continuous long-term holding approach.
| # | Ticker | Issuer | Asset Subclass | Weight | Weight Change | Shares Change | 4Q Trend |
|---|---|---|---|---|---|---|---|
| 1 | TARS | Tarsus Pharmaceuticals Inc | Stock-Other | 6.24% | +0.25% | — | |
| 2 | EOLS | Evolus Inc | Stock-Other | 5.36% | -0.10% | EXIT | |
| 3 | 4XC1 | Kalvista Pharmaceuticals Inc | Stock-Other | 5.06% | -4.68% | EXIT | |
| 4 | MIRM | Mirum Pharmaceuticals Inc | Stock-Other | 4.48% | +0.77% | +8.42% | |
| 5 | ANAB | Anaptysbio Inc | Stock-Other | 3.40% | +0.33% | — | |
| 6 | ANIP | Ani Pharmaceuticals Inc | Stock-Other | 2.92% | -0.10% | +200.00% | |
| 7 | DVAX | Dynavax Technologies CORP | Stock-Other | 2.86% | — | — | |
| 8 | LLY | Eli Lilly & Co | Stock-Healthcare | 2.49% | — | — | |
| 9 | ACAD | Acadia Pharmaceuticals Inc | Stock-Healthcare | 2.48% | — | +189.07% | |
| 10 | PCVX | Vaxcyte Inc | Stock-Other | 2.31% | — | — | |
| 11 | PTCT | Ptc Therapeutics Inc | Stock-Healthcare | 2.18% | +0.37% | — | |
| 12 | ITCIEUR | Intra-cellular Therapies Inc | Stock-Other | 2.09% | — | +100.00% | |
| 13 | ALT | Altimmune Inc | Stock-Other | 1.86% | -0.01% | — | |
| 14 | VRDN | Viridian Therapeutics Inc | Stock-Other | 1.85% | -0.28% | +101.02% | |
| 15 | ✓ | Avadel Pharmaceuticals PLC ADR | Stock-Other | 1.76% | — | — | |
| 16 | CRSP | CRISPR Therapeutics AG | Stock-Healthcare | 1.74% | — | +171.67% | |
| 17 | RCKT | Rocket Pharmaceuticals Inc | Stock-Other | 1.64% | — | +13.64% | |
| 18 | CGEM | Cullinan Therapeutics Inc | Stock-Other | 1.64% | — | +61.28% | |
| 19 | AUPH | Aurinia Pharmaceuticals Inc | Stock-Other | 1.62% | +0.85% | +35.59% | |
| 20 | GSK | Gsk Plc-spon Adr | Stock-Healthcare | 1.57% | — | +33.33% | |
| 21 | JAZZ | Jazz Pharmaceuticals plc | Stock-Healthcare | 1.52% | — | — | |
| 22 | AVIR | Atea Pharmaceuticals Inc | Stock-Other | 1.51% | -0.30% | +9.81% | |
| 23 | NVDA | Nvidia CORP | Stock-Tech | 1.45% | — | +1050.19% | |
| 24 | IMCR | Immunocore Holdings Plc-adr | Stock-Other | 1.40% | -0.24% | — | |
| 25 | LENZ | Lenz Therapeutics Inc | Stock-Other | 1.32% | -0.09% | +36.52% | |
| 26 | VNDA | Vanda Pharmaceuticals Inc | Stock-Other | 1.24% | — | +22.93% | |
| 27 | OTLK | Outlook Therapeutics Inc | Stock-Other | 1.22% | — | — | |
| 28 | AZNN | Astrazeneca Plc-spons Adr | Stock-Other | 1.19% | — | — | |
| 29 | KNSA | Kiniksa Pharmaceuticals International, plc | Stock-Other | 1.19% | +1.03% | — | |
| 30 | NUVB | Nuvation Bio Inc | Stock-Other | 1.12% | +0.16% | +5.63% | |
| 31 | APLT | Applied Therapeutics Inc | Stock-Other | 1.11% | — | +4.48% | |
| 32 | TORCEUR | Adicet Bio Inc | Stock-Other | 1.01% | — | +28.24% | |
| 33 | TDOC | Teladoc Health Inc | Stock-Healthcare | 1.00% | — | — | |
| 34 | CTMX | Cytomx Therapeutics Inc | Stock-Other | 0.97% | — | +20.81% | |
| 35 | CRGX | Cargo Therapeutics Inc | Stock-Other | 0.96% | — | +22.68% | |
| 36 | ZYME | Zymeworks Inc | Stock-Other | 0.95% | — | — | |
| 37 | IMNM | Immunome Inc | Stock-Other | 0.89% | — | — | |
| 38 | HRMY | Harmony Biosciences Holdings | Stock-Other | 0.86% | — | — | |
| 39 | ✓ | Elevation Oncology Inc | Stock-Other | 0.84% | — | — | |
| 40 | BIIB | Biogen Inc | Stock-Healthcare | 0.83% | -0.33% | EXIT | |
| 41 | BDTX | Black Diamond Therapeutics I | Stock-Other | 0.76% | — | — | |
| 42 | REPL | Replimune Group Inc | Stock-Other | 0.74% | — | — | |
| 43 | VTYXUSD | Ventyx Biosciences Inc | Stock-Other | 0.73% | — | — | |
| 44 | IONS | Ionis Pharmaceuticals Inc | Stock-Healthcare | 0.73% | — | — | |
| 45 | DNTH | Dianthus Therapeutics Inc | Stock-Other | 0.70% | +0.04% | — | |
| 46 | INSM | Insmed Inc | Stock-Healthcare | 0.68% | -1.68% | — | |
| 47 | HRTX | Heron Therapeutics Inc | Stock-Other | 0.66% | -0.13% | — | |
| 48 | VKTX | Viking Therapeutics Inc | Stock-Healthcare | 0.65% | +0.06% | +20.00% | |
| 49 | BEAM | Beam Therapeutics Inc | Stock-Other | 0.64% | — | — | |
| 50 | DTIL | Precision Biosciences Inc | Stock-Other | 0.62% | — | +5.73% |
According to official SEC Form 13F filings, Tang Capital Management LLC reported a total U.S. public equity portfolio value of $2.2B across 128 disclosed positions in Q2 2024.
Expert Analysis & Guides for Tracking Wall Street Smart Money Movements
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
In terms of portfolio concentration, the top 5 core holdings (including TARS, EOLS, 4XC1) accounted for 10.9% of total reported equity market value during Q2 2024.
During Q2 2024, Tang Capital Management LLC's top holdings by market value included TARS (6.2%)、EOLS (5.4%)、4XC1 (5.1%). The largest single position, TARS, represented 6.2% of total portfolio value.
In Q2 2024, Tang Capital Management LLC made 0 total portfolio adjustments, initiating 0 new buys, adding to 0 positions, trimming 0 holdings, and fully liquidating 0 stocks.
All holding records on this page are fetched directly from the U.S. Securities and Exchange Commission (SEC) EDGAR system (Form 13F-HR). AlphaSMO parses CUSIP identifiers and formats data into Schema.org-compliant datasets.
Understand SEC Form 4 insider disclosures for corporate officers, directors, and 10% owners to track executive transactions.
Understand Rule 144 restricted stock sale notices to spot planned insider liquidations before market sell pressure arrives.
Explore the 5% beneficial ownership threshold, 13D vs 13G filing differences, and recent SEC accelerated deadline rules.
Best practices for analyzing 13F quarterly changes without getting misled by stock splits, options, or market valuation drift.
Learn how AlphaSMO's flagship signal detects high-conviction stocks where 13F hedge funds and corporate insiders buy at the same time.